AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer treatment
The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck& Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Merck | Prostate Cancer